Home | Welcome to Contract Pharma   
Last Updated Sunday, May 24 2015

Print RSS Feed

Breaking News

Related Searches: Phase II Development Phase I cGMP
May 6, 2013
Will develop test to screen for mCRC  Read More »
May 6, 2013
Gains full control of cGMP manufacturing facility  Read More »
May 6, 2013
Will commit resources to global Oraxol, Oratecan  Read More »
May 3, 2013
Will use Ambrx's protein med-chem tech  Read More »
May 3, 2013
Deal worth as much as $50 million, plus royalties  Read More »
May 3, 2013
Expands market capabilities to include pharmaceutical use for Niacin  Read More »
May 3, 2013
Offers lab, office, and GMP production space for local pharma  Read More »
May 3, 2013
Revenues up 11% in the quarter with antiviral combos  Read More »
May 3, 2013
Specialty segment sales up 24% in the quarter  Read More »
May 2, 2013
Will combine methods for diabetes data collection  Read More »
May 2, 2013
Quart, Rosen, and Davis join management team  Read More »
May 2, 2013
To support diagnostic product development  Read More »
May 2, 2013
Earnings hit by lost generic Lipitor royalties  Read More »
May 2, 2013
Generic competition continues to hurt revenues  Read More »
May 2, 2013
Late-Stage Development revenues up 17%  Read More »



Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On